Allurion sees tailwind from weight loss drug frenzy
Allurion went public this week, and thinks the current focus on obesity can boost its own platform and products.
Stay updated with breaking news from Allurion Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Allurion went public this week, and thinks the current focus on obesity can boost its own platform and products.
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also include AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
Serial healthcare entrepreneur Douglas Hudson appointed to Board of Directors Tomer Stavitsky joins as VP of Corporate Development to lead M&A strategy focused on Artificial Intelligence ...
Allurion Technologies, Inc. and Compute Health Acquisition Corp. Announce Updated Terms to Warrant Agreement Amendment Warrant Holder Meeting to Take Place on...